Research
Metabolic adaptation
Semaglutide consistently produces substantial reductions in body weight and visceral fat, accompanied by improvements in blood pressure, glycemic control, inflammatory markers, and hepatic steatosis.
Practitioners can expect significant improvements in metabolic health markers with semaglutide use.
StrongSupportsmedium confidence
Across diverse studies, semaglutide consistently produces substantial reductions in body weight and visceral fat, accompanied by improvements in blood pressure, glycemic control, inflammatory markers, and hepatic steatosis.
Why this rating
Based on evidence from multiple studies including randomized trials.
Source
National Consensus on Semaglutide in Cardiology: From Clinical Evidence to Clinical Translation
HK Chopra et al. · Journal of the Association of Physicians of India · 2026
DOI 10.59556/japi.74.1375
Meta-analysisCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SELECT demonstrated a significant reduction in major adverse cardiovascular events in adults with overweight or obesity and established atherosclerotic cardiovascular disease, independent of diabetes status.Strong
- Semaglutide represents a practice-changing therapy that addresses core pathophysiological drivers of ASCVD and HFpEF through integrated modulation of adiposity and metabolic dysfunction.Strong
Related findings · Metabolic adaptation
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →